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Abstract
Influenza is common in infants and children: attack rates vary from 23% to 48% each year during inter-pandemic periods, and are even
higher during pandemics. Severe cases occur more frequently in children with underlying chronic diseases; however, epidemiological
studies have clearly shown that influenza also causes an excess of medical examinations, drug prescriptions and hospitalizations in other-
wise healthy children (particularly those aged <5 years), as well as a considerable number of paediatric deaths. Childhood influenza also
has a number of social and economic consequences. However, many European health authorities are still reluctant to include influenza
vaccinations in their national vaccination programmes for healthy children because, among other things, there are doubts concerning
their real ability to evoke a protective immune response, especially in children in the first years of life. New hope for the solution of
these problems has come from the introduction of vaccines containing more antigens and the possibility of intradermal administration.
However, further studies are needed to establish whether universal influenza vaccination in the first years of life should be recom-
mended, and with which vaccine.
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Introduction
Influenza is common in infants and children: attack rates vary
from 23% to 48% each year during inter-pandemic periods,
and are even higher during pandemics [1]. Severe cases
occur more frequently in children with underlying chronic
diseases; however, epidemiological studies have clearly
shown that otherwise healthy children (particularly those
aged < 5 years) can experience significant clinical problems
when infected by influenza viruses. Influenza causes a sub-
stantial excess of medical examinations, drug prescriptions
and hospitalizations in healthy children, and a number of
influenza-related deaths in paediatric subjects without any
risk condition [2–6]. Children are the main cause of the
spread of influenza in the community because they shed
greater amounts of virus for a longer time than adults. This
means that they frequently infect their own households and
give rise to various clinical, social and economic problems,
including parental absenteeism from work [7].
Yearly administration of influenza vaccine to children at
risk has been recommended by health authorities worldwide
for several years [8,9], but its use in healthy children is
widely debated. The most favourable attitude is found in the
USA, where healthy children aged 6–23 months have been
included in the list of subjects for whom influenza vaccination
should be recommended since 2003, and subsequent addi-
tions have led to universal vaccination being officially rec-
ommended for all subjects aged between 6 months and
18 years since 2008 [10]. This lead has been followed by a
number of Asian and Latin American countries although, in
most cases, vaccination is suggested only for healthy chil-
dren in the first years of life. In contrast, despite repeated
recommendations by multinational experts and advisory
groups [11–13], only six European countries (Austria, Esto-
nia, Slovakia, Latvia, Slovenia and Finland) have included
influenza vaccine in the paediatric vaccination schedule
(Table 1) [14]. Moreover, although Finland has imple-
mented a fully reimbursed vaccination programme for
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healthy children, this is limited to subjects aged 6–
35 months [15].
There are two main reasons for the reluctance of many
European health authorities to include influenza vaccination
in their national vaccination programmes. The first is their
widespread conviction that, although very common, influenza
in healthy children is always very mild and therefore does
not need to be prevented by vaccination. The second is that
there are doubts concerning the real ability of the available
vaccines to evoke a protective immune response in children,
particularly those in the first years of life. Data regarding the
total burden of childhood influenza collected over the last
10 years [1–7] indicate that the first assumption is probably
wrong, and that influenza in healthy children (particularly the
youngest) gives rise to a substantial medical and economic
burden that largely justifies prevention. However, it is signifi-
cantly more difficult to establish whether the available vac-
cines are effective enough to support their universal use in
healthy children, and two recent meta-analyses have reached
opposing conclusions [16,17].
As the course of influenza can be worst in children aged
<5 years, the main aim of this review is to discuss whether
the currently available data concerning the efficacy of influ-
enza vaccines justifies their universal use in healthy children
of this age.
Injectable influenza vaccines
Trivalent inactivated vaccines
Trivalent inactivated vaccines (TIVs; split-virus and subunit
TIVs) are the only injectable preparations that are licensed
for paediatric use throughout the world. Modern TIVs are
very different from the monovalent products containing one
whole killed virus (mainly type A) that were first prepared
more than 40 years ago [18] because they usually contain
fractions of three viruses, the most important of which in
immunological terms are the haemagglutinin of each. The
three viral strains are chosen every year on the basis of
WHO indications of the most probable causes of seasonal
influenza epidemics.
Throughout the world, TIVs are only licensed for children
aged ‡6 months. Moreover, it is recommended that previ-
ously unvaccinated children until the age of 9 years in some
countries and until the age of 3 years in other countries
should be given two TIV doses 1 month apart [8,9]. How-
ever, antibody production after TIV administration increases
with age: Walter et al. [19] studied children aged 6–
23 months in two consecutive years, and found that signifi-
cantly higher proportions of the older subjects achieved se-
roprotective antibody concentrations or a four-fold increase
in geometric mean titres. Nevertheless, the majority of the
youngest children had significantly high levels of antibodies
against influenza antigens, which suggests that, although the
correlate of protection for children has never been estab-
lished, some protective efficacy is possible in younger sub-
jects [19]. Unfortunately, there are very few data concerning
the immunogenicity of TIVs in children <2 years of age and
no definite conclusions can yet be drawn.
Evaluating the data from other studies of the efficacy and
effectiveness of TIVs in children is more difficult because
there are frequent differences in their endpoints (i.e. the
prevention of infection or diseases), the methods used to
evaluate them (i.e. seroconversion, seroprotection, culture
or PCR), and the characteristics of the children themselves.
However, when the few comparable studies are considered
together, they clearly show that TIVs are efficacious in pre-
venting influenza in children aged >3 years, although the
reduction in the number of disease cases is less than that
usually reported for other paediatric vaccinations. Using the
pooled results of five studies [20–24] of children aged
<9 years, Zangwill and Belshe [20] found that the efficacy of
TIVs was 63%, which, together with the indirect advantages
of preventing paediatric influenza, may justify the universal
use of TIVs in healthy children aged >3 years [25].
However, the efficacy of TIVs is significantly less when the
viral strains included in the vaccine do not perfectly match
those circulating in the community during an epidemic. Hei-
kkinen and Heinonen [26] examined the data collected in
ten clinical trials [22,24,27–34] that evaluated the efficacy of
TIVs in children aged <5 years using laboratory tests to con-
firm the diagnosis of influenza, and found that the protection
offered by these vaccines strictly related to the degree of
matching: when matching was very good, efficacy was always
60% or more (and in some cases higher than 80%); in the
case of a poor match, it was always less than 60%, and
sometimes near 0% [26]. The best example in this regard is
TABLE 1. Influenza vaccination recommendations
WHO/Europe
Recommend that member states vaccinate all individuals ‡6 months [1]
EU
Six member states currently recommend paediatric vaccination [2–4];
recommendations vary by country:
6 months to <18 years of age: Austria, Estonia and Slovakia
6–35 months: Finland
6–24 months: Slovenia, Latvia
USA, Canada and PAHO countries
USA: All individuals ‡6 months of age [5]
Canada: Children 6–24 months of age, and encourages all individuals
‡6 months of age to be vaccinated [6]
Currently, 27 PAHO countries and territories recommend paediatric
seasonal influenza vaccination [7]a
PAHO, Pan American Health Organization.
aPAHO recommendations vary by country or territory.
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provided by the 3-year case–control analysis of infants aged
6–23 months carried out by Cochran et al. [31]; this found
no efficacy during the first two influenza seasons in which
the vaccine strains were largely mismatched with the circu-
lating strains, and an efficacy of 59% during the third year
when the match was much better. A strict relationship
between vaccine match and vaccine efficacy is also acknowl-
edged in adults [35]. As in the case of immunogenicity, there
are very few published data relating to children aged
<2 years and it is not possible to state whether TIV adminis-
tration is really beneficial.
The administration of a larger amount of antigens and the
use of the intradermal route have both been tried to over-
come the problem of younger children’s relatively lower
immune response to TIVs. An increase in antibody production
after the administration of a larger amount of influenza virus
antigens has been found in adults [36], and Skowronski et al.
[37] confirmed this finding in a study of naive infants aged 6–
11 months: the administration of two doses of 0.5 mL
(instead of the conventional paediatric dose of 0.25 mL rec-
ommended for children aged <36 months) evoked signifi-
cantly higher antibody levels against all of the antigens
included in the vaccine, hence increasing the probability of
protection from infection and disease. Although there was no
increase in the incidence of adverse events in the children
receiving the double dose, further studies are needed to
confirm its immunogenicity, safety and tolerability before it
can be included in the vaccination schedule of young infants.
The intradermal administration of TIVs has led to interest-
ing results in the elderly, but paediatric data are limited to
one study of already primed children aged >3 years in whom
this route of administration evoked a protective immune
response [38]. However, the lack of data regarding children
aged <2 years does not allow the suggestion of this form of
administration as a means to overcoming the lower immuno-
genicity of TIVs.
It can therefore be concluded that administering TIVs may
be beneficial in some young children, although the level of
protection may be slightly lower than that observed in older
subjects. However, as conclusive data are available only for
children aged >2 years, nothing can be said about younger
subjects. The attempts to increase the immune response and
protection by using adjuvants, more antigens and a different
route of administration deserve consideration but still need
further documentation.
Adjuvanted TIVs
The goal of vaccination is to generate a strong immune
response to the administered antigen, one that is able to
provide long-term protection against an infection. To achieve
this objective with vaccines based on insufficiently immuno-
genic antigens, it is usually necessary to add an adjuvant. Adju-
vant is a term derived from the Latin word adjuvare, which
means to aid or to help and it was first coined by Ramon in
1926 [18]. It has been shown that virosomes and oil-in-water
emulsions can increase the immune response to antigens.
Virosome-adjuvanted vaccine. Virosome-adjuvanted vaccine
(VAV) is the only adjuvanted influenza vaccine licensed for
use in children in some European countries, but it is not reg-
istered in the USA. Virosomes consist of phospholipids that
spontaneously form virus-like vesicles to which the influenza
virus surface glycoproteins neuraminidase and haemagglutinin
are anchored [39], so allowing the development of a com-
pound that is structurally similar to the native virus.
In comparison with conventional TIVs, VAV leads to clo-
ser interactions with B lymphocytes and antigen-presenting
cells, a stronger T helper 1 response, and greater immune
stimulation. The immunogenicity of VAV in humans has been
demonstrated in a number of studies of adults and healthy
children of any age, but the data regarding younger subjects
are limited to a single study in which Kanra et al. [40] admin-
istered VAV or conventional split TIV to children aged 6–
71 months (with a considerable number of children younger
than 36 months) and found that the former was slightly
more immunogenic. The rates of seroprotection against A/
H3N2, A/H1N1 and B influenza viruses were, respectively,
87.8%, 80.1% and 90.4% in the children receiving VAV, and
82.9%, 78.2% and 89.4% in those treated with TIV [40]. The
authors also found that the rate of seroprotection against A/
H3N2 in unprimed children was significantly higher after
VAV (88.8% vs. 78.3%; p 0.03) [40].
The good immune response evoked by VAV was con-
firmed by data collected by our group in a study of unprimed
healthy children aged 6–35 months [41]. The official recom-
mendations state that two half-doses 1 month apart are
needed to obtain protection in previously unvaccinated chil-
dren of this age but, as compliance with this regimen is poor
and leaves a considerable number of children unprotected,
we evaluated a single dose containing all of the antigen usu-
ally administered with the two doses (i.e. 15 lg of each).
The results showed that this was as immunogenic as the tra-
ditional two doses, suggesting that it improves the stimula-
tion of the immune system [41].
The published data clearly suggest that VAV can evoke a
substantial and protective immune response in children aged
6–35 months, but efficacy studies have only included subjects
aged >2 years. The available data show that VAV is 84.4%
effective in preventing laboratory confirmed influenza A in
children aged 3–14 years [42]. We have studied children
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aged 2–5 years, and found that VAV is associated with a sig-
nificantly lower incidence of upper and lower respiratory
tract infections, febrile respiratory illnesses, drug prescrip-
tions, missed school days and lost parental working days than
no vaccination [43].
Although very few, all of these findings indicate that VAV
is a reasonable alternative to TIVs in children aged >2 years,
but further studies are needed to establish its immunogenic-
ity and efficacy in children aged <2 years. The data are still
too scanty to support its universal use.
Oil-in-water vaccines. Oil-in-water emulsions are simply drop-
lets of oil in water (100 nm), the most common of which
are squalene and tocopherol and tween and lecithin, which
can act as adjuvants to increase a vaccine’s immunogenicity.
Most of the data regarding oil-in-water adiuvanted vaccines
have been collected using the so-called MF59 compound, a
squalene-based emulsion that has been widely used since 1997
to increase the immunogenicity of various vaccines including
TIV. However, this adjuvant is not currently licensed for use
in children, mainly because there are still some unanswered
questions concerning its safety and tolerability as it seems to
cause transient local solicited reactions more frequently.
Nevertheless, although limited, the data regarding the use
of MF59-adjuvanted influenza vaccine (MF59-AV) in patients
aged 6–35 months seem to be very promising. Vesikari et al.
[44] administered two half-doses of MF59-AV or a conven-
tional TIV to unprimed healthy children aged 6–35 months,
and found that the haemagglutination inhibiting antibody ti-
tres against all of the three vaccine strains were significantly
higher after each vaccine dose in the children receiving
MF59-AV, who also showed significantly greater cross reac-
tivity against mismatched A strains. Moreover, in a second
study, the same authors showed that MF59-AV administered
to children under 36 months of age confers longer protec-
tion than conventional TIV and, when given as a booster to
subjects primed with the same vaccine, evokes a greater
immune response [45]. Finally, they have also shown that
MF59-AV is significantly more effective in children aged 6–
35 months, with absolute vaccine efficacy rates against all
influenza strains (94 of 110 cases were the result of vaccine-
matched H3N2 viruses) of 86% (95% CI 74–93) for the
MF59-AV and 43% (95% CI 15–61) for the vaccine without
the adjuvant (TIV); the relative vaccine efficacy rate for
MF59-AV versus TIV was 75% (95% CI 55–87). The efficacy
rates for MF59-AV were 79% (95% CI 55–90) in children
aged from 6 to <36 months and 92% (95% CI 77–97) in
those aged from 36 to <72 months of age, compared with
40% (95% CI )6 to 66) and 45% (95% CI 6–68), respectively,
for TIV [46].
The immunogenicity induced by the presence of MF59 in
influenza vaccines administered to children aged <2 years is
further supported by data collected by our group in a study
of prematurely born children aged 6–23 months who
received the monovalent MF59-AV specifically prepared for
the recent A/H1N1/2009 pandemic [47]. Although unprimed,
the children seroconverted and remained seroprotected
even after a single administration of a reduced dose of the
antigen contained in the vaccine, which introduces the idea
of spare antigen. Although the pandemic antigen was very
strong and the immunogenicity data relating to a pandemic
vaccine cannot be compared with those relating to a sea-
sonal vaccine, this finding suggests that MF59 plays a signifi-
cant role in favouring an optimal immune response;
however, further data on the possible future appearance of
rare but severe clinical conditions (including narcolepsy and
other neurological and autoimmune disorders) are required.
The second oil-in-water adjuvant (the so-called AS03 prepa-
ration) is conceptually similar to MF59, but the data regarding
its use in children are limited to the pandemic vaccine, and
there are no published data concerning its addition to seasonal
TIVs. Studies have shown that the AS03-adjuvanted vaccine
evokes a protective immune response even in unprimed chil-
dren aged 6–35 months, although the incidence of adverse
events (including high fever) was particularly high, especially in
the youngest patients [48]. Moreover, its use in Scandinavia has
been associated with a significant increase in the occurrence of
narcolepsy, a problem not found in other countries [49].
In conclusion, oil-in-water-adjuvanted vaccines seem to be
very interesting products because the few data collected in
children aged <36 months suggest that they induce a signifi-
cantly greater and broader immune response in children at
the highest risk of influenza-related complications who have
the lowest immune response to conventional TIVs. However,
before they can be considered a real means of improving the
efficacy of influenza vaccines in younger patients, further
studies are needed and, in particular, more data are required
concerning the safety and tolerability of AS03.
Live attenuated influenza vaccine
Nasally administered live attenuated influenza vaccine (LAIV)
contains cold-adapted, temperature-sensitive, attenuated
influenza viruses. It induces a stronger response than TIVs
because it mimics natural influenza infection, evoking both
mucosal and systemic immunity (including cellular immune
response); it is also more easily accepted by children because
it does not require an intramuscular injection. In the USA, it
was approved for use in healthy subjects aged 2–49 years in
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2003 [50] but, in Europe, it has only been authorized for
subjects aged 2–18 years [51]. In both areas, it is not recom-
mended for children aged <2 years, children under the age
of 5 years with a history of acute wheezing, children and
adults with severe asthma, or patients who take medications
that can weaken the immune system [50,51].
The immunogenicity of LAIV has been evaluated in sub-
jects of all ages, including children aged 6–72 months. The
most important information coming from the studies of chil-
dren aged 15–55 months is that LAIV evokes a significantly
higher level of systemic antibodies than TIVs, and that a
number of subjects (62–89% depending on the viral strain
included in the vaccine) develop a significant mucosal IgA
response [52–57]. It has also been found that primed chil-
dren are 4.5 times more likely to develop a mucosal immune
response than a systemic antibody response, indicating that
the mucosal response facilitated by the cellular immune
response induced by LAIV is probably the main reason for
the postulated superiority of LAIV [58].
Various studies have measured the efficacy of LAIV against
placebo and TIV [52–57]. A meta-analysis of placebo-con-
trolled trials in which the recommended two doses of LAIV
were administered to unprimed healthy children aged 6–
71 months found an estimated efficacy of 77% for antigeni-
cally similar subtypes of all three vaccine strains in the vac-
cine, and 72% for all subtypes regardless of antigenic
similarity [58]. A separate analysis of the children aged
<36 months showed that age did not significantly affect effi-
cacy, which was 74% for antigenically similar subtypes and
69% for all strains [58]. Moreover, the immune response
induced by LAIV was maintained over time: 1 year after hav-
ing received the first two-dose vaccination 87% of the chil-
dren were protected against antigenically similar subtypes
and 76% against all the circulating subtypes [58].
The studies carried out by Belshe et al. [59] provide the
best evaluation of LAIV efficacy in children aged <2 years.
They monitored the efficacy of LAIV and TIV against culture-
confirmed influenza in subjects aged 6–59 months (50% of
whom were 6–23 months old), and found 54.9% fewer cases
of disease in the group receiving LAIV [59]. The efficacy of
LAIV was almost 90% against A/H1N1 and 80% against A/
H3N2 influenza viruses, whereas there was no significant dif-
ference in the efficacy of the two vaccines against B virus
[59]. Furthermore, unlike TIV, LAIV was also effective against
poorly matching variants of the A/H3N2 virus [59].
Unfortunately, the good immunogenicity and efficacy of
LAIV in younger children was associated with an increased
risk of wheezing in the youngest. Wheezing was observed
within 42 days of vaccination in 3.8% of the children aged
<2 years, but in only 2.1% of those receiving TIV, whereas
children ‡2 years could tolerate the vaccine without any risk
of bronchospasm [59]. Other studies have not found the
same problem [60–62] and have not found the same risk of
wheezing, which nevertheless must still be considered as
greatly limiting the use of LAIV in infants and young children.
Furthermore, the risk of bronchospasm is the main reason
why the USA and European health authorities have not
licensed LAIV for use in children younger than 2 years or in
those who have previously experienced severe obstructive
respiratory problems.
Preventing influenza in children aged
<6 months
As stated above, none of the available influenza vaccines is
recommended for children aged <6 months because their
immune response is considered too small to achieve protec-
tion, especially during the last trimester of pregnancy. A
paper by Glezen’s group from the 1980s searched for influ-
enza in children <6 months of age and found maternally
transferred antibody, suggesting that in these young infants
the immune response postvaccination could be hampered
and they could be protected by maternal antibodies [63].
However, as influenza can be dangerous in such subjects,
repeated attempts have been made to prevent infection and
the consequent disease by immunizing pregnant women. Cir-
culating IgG antibodies and IgA antibodies secreted in breast
milk may protect infants [64,65], and a number of studies
have shown that up to 6 months of age the children of
mothers vaccinated during pregnancy have significantly higher
antibody levels than those of unvaccinated mothers [66–68].
The efficacy of vaccination during pregnancy in preventing
infantile influenza has been investigated in various studies,
which have found reductions in the incidence of influenza dis-
ease in the first 6 months of life ranging from 41% to >90%
[69–73]. This explains why most experts suggest administer-
ing TIV during pregnancy, particularly in the last two trimes-
ters (LAIV must not be used because it is based on live
viruses). Unfortunately, compliance with this recommendation
is poor in both the USA (where the use of TIV is officially rec-
ommended) [73,74] and Europe (where only a limited number
of countries include pregnant women among the subjects for
whom influenza vaccine is strongly recommended) [73,75].
Conclusions
Analysis of the currently available data concerning the impact
of influenza on children and the effects of influenza vaccina-
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tion suggest that influenza prevention is needed to reduce
disease-related medical, social and economic problems.
Unfortunately, although prevention by means of vaccines is
satisfactory in older children, it is not the case in those aged
<2 years, in whom the immunogenicity of conventional TIVs
seems to be reduced. For this reason, and the fact that their
efficacy has rarely been evaluated in randomized, placebo-
controlled and blinded studies, no firm conclusions can be
drawn concerning their possible use in children younger than
2 years. Among the adjuvanted TIVs, VAV has been poorly
investigated in children aged <2 years and, despite their
greater immunogenicity, oil-in-water adjuvanted TIVs have
not yet been licensed because of the lack of adequate safety
and tolerability data. It was initially thought that LAIV might
provide the best solution, but the emergence of post-
administration respiratory problems does not allow its use
in children aged <2 years, who are at higher risk of influ-
enza-related complications. Consequently, the possibility of
preventing influenza in children aged 6–23 months by means
of the currently available vaccines still remains an open
question. Administering a TIV containing more antigens or
using the intradermal route offer new hope that a definite
solution can be found, but further studies are needed to
define whether universal influenza vaccination in the first
years of life should really be recommended, and with which
vaccine. In the meantime, cocooning strategy around the
most vulnerable infants (i.e. those with risk factors for
complicated disease) should be implemented everywhere
and the public health issue represented by influenza in chil-
dren should be adequately considered at least on a Euro-
pean level.
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